TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA

PHASE4CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2016

Conditions
Chronic Hepatitis B
Interventions
DRUG

Lamivudine plus adefovir

Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks

DRUG

Tenofovir

Tenofovir 300mg QD for 96 weeks

Trial Locations (1)

"ASI

Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu

All Listed Sponsors
collaborator

Kyungpook National University Hospital

OTHER

collaborator

Daegu Catholic University Medical Center

OTHER

collaborator

DongGuk University

OTHER

collaborator

Pusan National University Hospital

OTHER

collaborator

Yeungnam University Hospital

OTHER

lead

Keimyung University Dongsan Medical Center

OTHER

NCT01732367 - TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA | Biotech Hunter | Biotech Hunter